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High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML -NO

Christian Enzinger
Since its first implementation in the diagnostic criteria more than 15 years ago, based on scientific progress and paralleled by cumulative clinical confidence in its interpretation, magnetic resonance imaging (MRI) of the brain has gained an increasingly important, now firmly established, role in the diagnosis and differential diagnosis of multiple sclerosis (MS). 1 Moreover, MRI may also provide further information relevant for managing patients with MS concerning prognosis, treatment decisions, and, more recently, monitoring disease activity and efficacy of treatments. 2 Given these achievements and its high sensitivity, it is thus self-evident to also advocate a role for MRI in detecting side effects associated with a treatment, including opportunistic infections. Accordingly, in 2016, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee updated recommendations to minimize the risk of the rare brain infection progressive multifocal leukoencephalopathy (PML) with natalizumab treatment in MS, suggesting to consider more frequent MRI scans for patients at higher risk. 3 While the author's position certainly is not to contradict this recommendation, it shall rather serve to also critically highlight potential drawbacks and practical challenges, both for radiologists and neurologists, implicated with such an approach.
However, before detailing concerns regarding reliable detection of asymptomatic PML in natalizumabtreated MS patients using high-frequency MRI, it appears insightful to first scrutinize the performance of established, scientifically validated, and formalized radiological criteria in easier situations. Given the wealth of knowledge on the morphology and pattern of distribution of MS lesions and the algorithms implicated in diagnostic criteria to ascertain dissemination in space (DIS) and dissemination in time (DIT), one would expect high concordance rates in their application among radiologists in academic settings. However, a study from Amsterdam argues against this. 4 Four radiologists trained and four radiologists naive in the application of the International Panel (IP) criteria 2001 scored fulfillment for DIS and DIT in baseline and follow-up scans from patients suspected for having MS. The IP-trained radiologists agreed at least moderately on all assessments (kappa > 0.40), whereas IP-naive radiologists only showed fair agreement (kappa < 0.40) on 5 of 16 assessments. While, meanwhile, the criteria have been simplified, the limited agreement especially among IP-naive radiologists (who yet had been working in public hospitals for several years, and had ample experience with MRI and MS in general diagnostic setting) highlights the difficulties that need to be expected in the much more complex situation of evaluating a patient at high risk of PML.
A study from a Cleveland MS specialty clinic further substantiates these concerns. 5 On paired brain MRI scans from MS patients separated by 6 months obtained using a standardized protocol, the number of new T2-lesions, newly enlarging T2-lesions, and enhancing lesions were measured using a computerbased image analysis program. Images were reanalyzed by an expert neuro-radiologist and three clinician raters (after modification of images to simulate clinical practice). Agreement on lesion counts was highest for enhancing lesions, intermediate for new T2-lesions, and poor for enlarging T2-lesions (concordance correlation coefficients ranging from 0.80 to 0.96, 0.60-0.70, and 0.00-0.14, respectively). In 18% of the cases, MRI activity was classified differently by the clinician raters compared with the neuroradiologist. 5 The implications in managing MS patients become readily visible, if one considers current scores to predict treatment response based on distinct lesion number cut-offs. 2 Together, these findings emphasize the difficulties in transferring the radiologic accuracy levels achieved at academic settings to real-world situations with less experienced raters, let alone the issue of widely missing standardized MRI data acquisition in MS (for a proposal, see Rovira et al. 1 ) These issues become particularly relevant in the distinction of new focal T2-lesions in MS patients from a PML lesion at early stages (compare Figure 3 in Wattjes et al. 6 ) but are further complicated by a "moving diagnostic target." While in earlier days, the distinction between PML and MS lesions was regarded as relatively clear-cut, 7
with the increasing number of cases, the catalogue of MRI appearances of PML now has become extensive. 6 It is certainly for good reasons that experienced neuro-radiologists have termed natalizumab-associated PML "the chameleon of neuroinflammation." 6 In contrast to classical imaging characteristics of PML, MRI findings in natalizumab-associated PML, particularly in early disease stages (which high-frequency MRI monitoring seeks to capture), show rather heterogeneous imaging findings including different patterns of inflammation with contrast enhancement. 6 The challenges faced in less experienced hands when it comes to diagnose microcystic appearance of white matter PML lesions, cortical and deep gray matter manifestations or posterior fossa PML lesions 6 are easily conceivable. In the context of a highly effective MS treatment like natalizumab where lesion activity is very rare, effectively any new lesion thus could raise suspicion of PML.
In the scenario of high-frequency MRI monitoring for PML detection with the explicit aim to capture preclinical PML (i.e. without clinical suspicion), 8 the reporting radiologist thus would be prompted-also to be (both legally and diagnostically) on the safer side-to interpret any new lesion as "in principle suspicious of PML." The fact that this person, most likely, will not be a neuro-radiologist, will not mitigate this risk. Let alone logistic challenges, it is also inconceivable that the huge number of scans evoked by the new suggestion could be handled by the worldwide small numbers of experts. While desirable, due to lacking human (and in some countries certainly also technical and financial) resources, it appears unrealistic to request that MRI safety scans should be performed and reported by neuro-radiologists or radiologists trained in identifying PML. 8 However, if the above assumptions turned true, their clinical implications would indeed be profound. This situation would frequently result in stopping an effective treatment for unclear periods of time in formerly active MS patients (including the risk of recurring or rebounding MS activity), obtaining (sometimes repeated) cerebrospinal fluid (CSF) tests and-given the notorious difficulties in diagnosing PML 9 -often lead to diagnostic uncertainties, sometimes necessitating biopsies. The fact that even a negative CSF does not rule out PML 9 does not alleviate the management of such situations.
Furthermore, none of the features thought to be characteristic for PML in MS are really pathognomic. 6, 8 In particular, the characteristics of asymptomatic PML lesions are poorly characterized and based on small patient numbers. 10 In addition, while it appears intuitive that earlier cessation of natalizumab should be associated with less brain damage, further data are needed to confirm the impact of early PML identification on clinical outcomes, as also conceded by McGuigan et al. 8 Currently, given the clinical impact of natalizumab, neither a positive test for anti-JCV antibodies nor an anti-JCV antibody index >1.5 represent contraindications for natalizumab treatment, 8 although these represent useful risk stratification parameters. Consequently, the risks and benefits of this treatment need to be re-evaluated at appropriate intervals, determined by the patient's disease course and wishes. While there is a defined role of MRI in this scenario (with regulatory annual MRI scans), overreliance on high-frequency MRI, especially if not obtained at standardized conditions with central read-out by PMLexperienced neuro-radiologists, besides early PML detection, could lead to two further scenarios: incorrect perception of safety, on one hand ("exclusion" of PML via MRI), and prompting unnecessary cessation of therapy and further tests in case of equivocal MRI findings, on the other hand. Also, it is not yet known whether all patients developing PML pass through a pre-symptomatic phase with MRI abnormalities. 8
Finally and importantly, overreliance on MRI might also compromise clinical vigilance and in some cases falsely terminate further exploring the possibility of PML in case of MRI negative findings, as reported in 40% of PML patients (12/30) in some series. 11 Currently, the positive and negative predictive values of repeated MRI regarding a PML diagnosis are not known. The gain of frequent MRI thus remains unclear. While there should be no doubt to obtain a brain MRI scan irrespective of any algorithm in the event of unexpected clinical worsening or with uncommon clinical symptoms or signs, highfrequency MRI monitoring in natalizumab-treated MS patients with higher risk of PML will pose substantial problems in patient care, especially outside the world of academic MS centers. The additional scans will lead to diagnostic uncertainties, evoke unnecessary cessation of therapy in some cases for substantial time periods, and raise the burden of costs implied in MS therapy, with an unclear yield of diagnosis of early asymptomatic evolving PML lesions. However, the increasing therapeutic armamentarium in MS with new efficacious treatments on the horizon might finally make it unnecessary to push the boundaries in natalizumab-treated MS patients at high risk of PML in such a way.
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The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Christian Without any doubt, such recommendations create extra costs, take limited imaging resources, and may pose unnecessary burden to the patients. Are they sufficiently supported by class I evidence? Are they based on a solid cost-benefit analysis? The answer is: NO. Anecdotal evidence only suggests that strict MRI pharmacovigilance using brain MRI may lead to an earlier detection of PML (preferably at a pre-/ asymptomatic stage) and may associate with a better functional outcome following PML. 4 A suggested abbreviated brain MRI protocol including fluidattenuated inversion recovery (FLAIR), T2-weighted imaging, and diffusion-weighted imaging (DWI) has never prospectively been validated for these purposes. A substantial number of small asymptomatic PML lesions may be undetectable on DWI, 5 and the proposed scanning interval of 3-4 months is based on class IV evidence. Additionally, the potential challenges in interpretation of brain MRI in particular with respect to lesion differentiation (e.g. MS vs PML) are quite obvious [6] [7] [8] as also nicely elaborated in the position statement of Dr Enzinger. ("High frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML." "NO.") So, should we then generally omit the MRI screening in patients at high risk of PML? The answer is once again: NO. Fortunately, PML, although increasingly reported and recognized in therapy-induced immunosuppression, still is a rare disease. 9 It is almost impossible to provide class I evidence for a rare disease in a heterogeneous group of patients. As such, in the absence of evidence, expert opinions that guide clinicians and help to standardize patient care can be a valuable alternative. Absence of solid data does not call for omission of obtaining such data. Indeed, standardized protocols may help to move the field forward, allowing for more reliable interpretation of MRI in the context of suspicion of PML in the future, and the search for added diagnostic tools to earlier facilitate the diagnosis of PML. 10 Technical solutions such as a web-based MRI second opinion reporting platform providing easy access to a world-wide expert opinions may be developed, and help physicians reading and interpreting MRI scans (http://www.ixico. com/digital-health), possibly in the future even outside of diagnosing natalizumab-associated PML.
Overall, will MRI screening in patients at high risk of PML be feasible and should we perform it? We believe: YES. Although it is unclear to date how many patients are needed to be screened by MRI before preventing a single symptomatic case, or preventing severe sequelae of clinically manifest PML, drug development outruns this controversy and makes the YES practically
